Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NG101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
Details : NG101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : NG101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable